[Clinical experiences with polyethylene glycol-bound E. coli L-asparaginase in patients with multiple recurrences of acute lymphoblastic leukemia]

Klin Padiatr. 1988 May-Jun;200(3):184-9. doi: 10.1055/s-2008-1033707.
[Article in German]

Abstract

The efficiency and toxicity of E. coli-L-Asparaginase coupled to polyethyleneglycol (PEG-ASP) was investigated in 5 patients with second relapse of acute lymphoblastic leukemia. PEG-ASP was administered at a dose of 2000 U/m2 as infusion over 2 hrs. every 2 weeks. Following an initial single agent phase, PEG-ASP was combined with prednisone, vincristine, adriamycin and methotrexate i.t. Following induction, all 5 patients were in third remission. The remissions lasted from 3 to 9 months, median 4 months. The toxicity was transient and mild. Also in patients sensitized against native L-Asparaginase no anaphylactic reactions were observed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Asparaginase / adverse effects
  • Asparaginase / therapeutic use*
  • Child
  • Child, Preschool
  • Doxorubicin / administration & dosage
  • Drug Administration Schedule
  • Drug Evaluation
  • Female
  • Follow-Up Studies
  • Humans
  • Leukemia, Lymphoid / drug therapy*
  • Leukocyte Count / drug effects
  • Male
  • Methotrexate / administration & dosage
  • Polyethylene Glycols / adverse effects
  • Polyethylene Glycols / therapeutic use*
  • Prednisone / administration & dosage
  • Vincristine / administration & dosage

Substances

  • Polyethylene Glycols
  • Vincristine
  • pegaspargase
  • Doxorubicin
  • Asparaginase
  • Prednisone
  • Methotrexate